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Patient
Number
Disease
Stage/Age
Engrafted
CBU
Engraftment
Day
NiCord
Chimerism*
Months
post
Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128S118range 10 e 22, were enrolled (Feb 2007 e July 2012). All had
hepatomegaly. Median ferritin level was 3,500 ng/mL. All of
them received hydroxyurea (20 mg/kg/day) for at least 6
months. They also received sequential immunoablative
regimen consisted with 2 monthly cycles of ﬂudarabine 40
mg/m2 and dexamethasone 25 mg/m2 x 5 days prior to
conditioning regimen. The conditioning regimen consisted
with busulfan 130 mg/m2 x 4 days, ﬂudarabine 35 mg/m2 x 6
days and ATG 6 mg/kg. GVHD prophylaxis consisted with FK
506 or cyclosporine and MMF. All of them received periph-
eral blood stem cells with a target dose of CD34þ10 x 106
cells/kg. Eleven patients received matched related and 4
receivedmatched unrelated donor stem cells. Median time of
neutrophil and platelet engraftment was day þ10 and þ 15
respectively. Three patients had mild VOD. Four patients had
grade II-IV and none had grade III-IV GVHD. Five patients had
mild chronic GVHD which subsequently was resolved. All 15
patients achieved full (100%) donor chimerism at day þ30
and these chimerisms were sustainable. Overall and disease
free survival rates were 91.2 % (95%CI:50-96). No rejection
was observed. One patient died from cerebellar hemorrhage.
We suggest that our sequential immunoblative regimen prior
to conditioning regimen is a key factor for this favorable
outcome in these difﬁcult patients. We also proved that T cell
proliferation assay (stimulationwith PHA) was suppressed in
all patients after 2 cycles of sequential immunoablative
regimen. This could explain the immunoablative concept in
our study. Our novel approach may be suitable for transplant
in other non malignant diseases.Transplant
ANC
>500
Platelet
>20,000
CD15
(%)
CD3 (%)
1 AML
(CR1)/61
NiCord
þ UM
14 33 42 2 22
2 MDS
(Int-2)/43
NiCord 11 30 100 100 17
3 MDS
(Int-2)/59
NiCord 10 30 97 93 15
4 AML
(CR2)/41
UM 18 36 0 0 14
5 AML
(CR1)/57
UM 26 49 0 0 11
6 AML
(CR2)/45
NiCord 10 30 100%
(Whole
Blood)
8
7 HL/21 NiCord
þ UM
7 26 100 31 6
8 NHL/46 Graft
failure
- - - - 5z
9 AML
(CR1)/45
NiCord 14 41 97 61 2
10 AML
(PR)/59
NiCord 18 - >98
(Whole
Blood)
2y
11 ALL
(CR1)/44
NiCord 7 N/A 100 100 1
*Performed at date of last follow-up from peripheral blood.
yDeath Day 47 Pneumonia.
zRe-transplanted with haploidentical donor.18
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Human transplantation of expanded HPCs resulting in
durable, robust donor myeloid and T-cell engraftment has
yet to be reported. A pilot study of myeloablative dual UCB
transplantation where one UCB unit is expanded ex vivo
using NiCord technology has completed accrual. The NiCord
UCB graft consisted of an expanded CD133þ and an unex-
panded CD133- T-cell fraction. HPCs were expanded for 21
days in media containing cytokines supplemented with
nicotinamide (NAM). All patients were conditioned with TBI
(1350cGy), ﬂudarabine 160mg/m2 cyclophosphamide
120mg/kg (n¼2). GvHD prophylaxis consisted of tacrolimus
and MMF. Eleven patients (med. age 45; range 21-61) with
high-risk malignancies received NiCord and an UM graft
(Table). Both units were comparably HLA-matched with the
recipient; 4/6 (n¼7), 5/6 (n¼3) or 6/6 (n¼1) vs. 4/6 (n¼8), 5/6
HLA (n¼3), respectively. However, the UM unit containeda larger pre-cryopreserved cell dose (3 x 107/kg [range 1.9-
3.9] vs. 2.5 x 107/kg [range 1.7-3.8]). After expansion
(CD133þ fraction), NiCord contained a median TNC and
CD34þ cell dose of 2.7 x 107/kg (1.0-6.4) and 3.5 x 106/kg
(0.9-18.3), respectively. The NiCord T-cell dose was
substantially smaller than the UM graft.
Results: Eight patients engrafted with NiCord (one of which
is a mixed donor chimera) and twowith the UM graft (Table).
One patient experienced primary graft failure. The median
time to neutrophil engraftment was 12.5 days (7-26) for the
entire cohort, and 10.5 (7-18) days for those engrafting with
NiCord. Three patients experienced grade I/II acute GvHD.
There were no cases of Grade III/IV acute GvHD. No safety
concerns were raised. The estimated 100-day treatment-
related mortality is 10%. With a median follow-up of 8
months, the progression-free and overall survival are both
90%.
Conclusion: NiCord expanded HPC’s are capable of out-
competing those from the UM unit and predominate in the
majority of patients. NiCord expanded HPC’s reduce the time
to hematopoietic recovery and are capable of long term (>22
months) neutrophil and T-cell engraftment. Stem cell
transplantation using NiCord is feasible, and may provide
a potent cord blood graft enabling transplantation of a single
expanded unit, without co-infusion of UM cells.19
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